Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of
genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining …

In recent years, immunotherapies have been clinically investigated in AML and other
myeloid malignancies. While most of these are focused on stimulating the adaptive immune …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

Cancer progression involves the gradual loss of a differentiated phenotype and acquisition
of progenitor and stem-cell-like features. Here, we provide novel stemness indices for …

Refractoriness to induction chemotherapy and relapse after achievement of remission are
the main obstacles to cure in acute myeloid leukaemia (AML). After standard induction …

Molecular profiles of tumors and tumor-associated cells hold great promise as biomarkers of
clinical outcomes. However, existing data sets are fragmented and difficult to analyze …

Inflammation coordinates tissue regeneration via damaged cell removal and stem cell
activation. Hematopoietic stem cells (HSCs) survive inflammatory stress that kills other blood …

Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

Genetic analyses have shaped much of our understanding of cancer. However, it is
becoming increasingly clear that cancer cells display features of normal tissue organization …